BiOptix Diagnostics, a Boulder, CO-based developer of an analytical biosensor instrumentation, raised an additional $1.4m financing.
Existing investors Boulder Ventures, Remeditex and Rusnano provided the funds.
The company intends to use the capital to expand sales and marketing and ramp up manufacturing.
Led by Rick Whitcomb, President and CEO, BiOptix has developed a new class of analytical biosensor instrumentation utilizing ESPR – Enhanced Surface Plasmon Resonance. Its instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.
FinSMEs
14/08/2014